glp-1 receptor agonist atrial fibrillation risk HRS 2026 Insights: Glucagon-Like Peptide-1 Agonists Reduce Independently of Effects on Weight Loss and Survival GLP-1 Receptor Agonists in Heart

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are approved for type 2 diabetes (T2D), and some are also indicated for reduction of the risk of atherosclerotic CVD in T2D and for weight management

GLP-1 slows gastric emptying, inhibits glucagon release, and enhances insulin sensitivity

Glucagon-like peptide-1 receptor agonists for non-alcoholic fatty liver disease in type 2 diabetes: A meta-analysis

It has also been suggested that hepatic hypoinsulinemia may reduce insulin-like growth factor 1 (IGF-1) levels, which may contribute to IR as well by increasing growth hormone and IGF binding globulins (29)

This shortfall is particularly concerning because adequate protein is crucial to preserve lean muscle mass during weight loss, a factor critical for long-term metabolic health and weight management